125 related articles for article (PubMed ID: 2551693)
21. Treatment of vitamin D-resistant rickets with 25-hydroxycholecalciferol.
Pak CY; DeLuca HF; Bartter FC; Henneman DH; Frame B; Simopoulos A; Delea CS
Arch Intern Med; 1972 Jun; 129(6):894-9. PubMed ID: 4338211
[No Abstract] [Full Text] [Related]
22. Vitamin D-dependent rickets Type II with alopecia: two case reports and review of the literature.
Sultan Al-Khenaizan ; Vitale P
Int J Dermatol; 2003 Sep; 42(9):682-5. PubMed ID: 12956677
[TBL] [Abstract][Full Text] [Related]
23. Two siblings with vitamin-D-dependent rickets type II: no recurrence of rickets for 14 years after cessation of therapy.
Takeda E; Yokota I; Kawakami I; Hashimoto T; Kuroda Y; Arase S
Eur J Pediatr; 1989 Oct; 149(1):54-7. PubMed ID: 2558018
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D-dependency rickets in institutionalized, mentally retarded children on long term anticonvulsant therapy. II. The response to 25-hydroxycholecalciferol and to vitamin D2.
Maclaren N; Lifshitz F
Pediatr Res; 1973 Nov; 7(11):914-22. PubMed ID: 4356082
[No Abstract] [Full Text] [Related]
25. Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.
Fraser D; Kooh SW; Kind HP; Holick MF; Tanaka Y; DeLuca HF
N Engl J Med; 1973 Oct; 289(16):817-22. PubMed ID: 4357855
[No Abstract] [Full Text] [Related]
26. Immune dysfunction in hypophosphatemic vitamin D-resistant rickets: immunoregulatory reaction of 1 alpha(OH) vitamin D3.
Kitajima I; Maruyama I; Matsubara H; Osame M; Igata A
Clin Immunol Immunopathol; 1989 Oct; 53(1):24-31. PubMed ID: 2548783
[TBL] [Abstract][Full Text] [Related]
27. Premature cranial synostosis in X-linked hypophosphatemic rickets: possible precipitation by 1-alpha-OH-cholecalciferol intoxication.
Carlsen NL; Krasilnikoff PA; Eiken M
Acta Paediatr Scand; 1984 Jan; 73(1):149-54. PubMed ID: 6538374
[TBL] [Abstract][Full Text] [Related]
28. [A report on two siblings with vitamin D resistant rickets treated with 1 alpha-hydroxy-vitamin D3 until completion of the growth].
Yoshikawa S; Ohno A; Amagai H; Ikeda K
Nihon Seikeigeka Gakkai Zasshi; 1992 Nov; 66(11):1137-45. PubMed ID: 1336532
[TBL] [Abstract][Full Text] [Related]
29. Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets.
Patel L; Clayton PE; Brain C; Pelekouda E; Addison GM; Price DA; Mughal MZ
Clin Endocrinol (Oxf); 1996 Jun; 44(6):687-96. PubMed ID: 8759181
[TBL] [Abstract][Full Text] [Related]
30. Long-term treatment of familial hypophosphatemic rickets with oral phosphate and 1 alpha-hydroxyvitamin D3.
Rasmussen H; Pechet M; Anast C; Mazur A; Gertner J; Broadus AE
J Pediatr; 1981 Jul; 99(1):16-25. PubMed ID: 6265614
[TBL] [Abstract][Full Text] [Related]
31. Rickets with alopecia: an inborn error of vitamin D metabolism.
Rosen JF; Fleischman AR; Finberg L; Hamstra A; DeLuca HF
J Pediatr; 1979 May; 94(5):729-35. PubMed ID: 221630
[TBL] [Abstract][Full Text] [Related]
32. Vitamin D-resistant rickets and 25-hydroxycholecalciferol.
Manis J; Norman A
Br Med J; 1975 May; 2(5969):478-9. PubMed ID: 167901
[No Abstract] [Full Text] [Related]
33. Hypophosphataemic vitamin-D resistant rickets may need phosphate supplements.
Price HV; Woodhead JS
Br Med J (Clin Res Ed); 1982 May; 284(6327):1442-3. PubMed ID: 6282378
[No Abstract] [Full Text] [Related]
34. Successful treatment of genetically hypophosphatemic mice by 1 alpha-hydroxyvitamin D3 but not 1,25-dihydroxyvitamin D3.
Beamer WG; Wilson MC; DeLuca HF
Endocrinology; 1980 Jun; 106(6):1949-55. PubMed ID: 6892799
[TBL] [Abstract][Full Text] [Related]
35. Actions of 1,25-dihydroxycholecalciferol in patients with hypophosphatemic, vitamin-D-resistant rickets.
Brickman AS; Coburn JW; Kurokawa K; Bethune JE; Harrison HE; Norman AW
N Engl J Med; 1973 Sep; 289(10):495-8. PubMed ID: 4353218
[No Abstract] [Full Text] [Related]
36. Treatment of hypophosphataemic vitamin D-resistant rickets.
Kristiansen JH; Pedersen VF
Arch Dis Child; 1981 Jan; 56(1):76-7. PubMed ID: 6258488
[No Abstract] [Full Text] [Related]
37. The combined use of intravenous and oral calcium for the treatment of vitamin D dependent rickets type II (VDDRII).
al-Aqeel A; Ozand P; Sobki S; Sewairi W; Marx S
Clin Endocrinol (Oxf); 1993 Aug; 39(2):229-37. PubMed ID: 8396512
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D--resistant rickets: end-organ unresponsiveness to 1,25(OH)2D3.
Sockalosky JJ; Ulstrom RA; DeLuca HF; Brown DM
J Pediatr; 1980 Apr; 96(4):701-3. PubMed ID: 6244382
[No Abstract] [Full Text] [Related]
39. The management of siblings with familial hypophosphatemic rickets.
Lapatsanis PD; Sbyrakis S; Megreli C; Edelstein S
Helv Paediatr Acta; 1983 Oct; 38(4):373-81. PubMed ID: 6654689
[TBL] [Abstract][Full Text] [Related]
40. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1alpha-hydroxyvitamin D3.
Peacock M; Heyburn PJ; Aaron JE
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():231s-237s. PubMed ID: 203418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
